^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    FirstSight™ CRC Test

    Company:
    CellMax Life
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    5ms
    Multisite external validation of blood test for colorectal neoplasia screening in a majority average-risk screening cohort of 449 subjects. (ASCO-GI 2024)
    An external validation included 449 subjects from a multi-site, majority average-risk CRC screening study successfully validated the FirstSight Blood Test’s high performance as previously established with 1,038 subjects. The results bring forth confidence in the Test’s reproducibility in a large-scale clinical trial. Clinical trial information: NCT05127096.
    Clinical
    |
    FirstSight™ CRC Test
    over1year
    CellMax Life announces positive results from prospective multisite study of novel blood test to detect colorectal cancer and pre-cancer (PRWeb)
    "CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer, as well as advanced adenomas."
    Clinical data
    |
    FirstSight™ CRC Test